Loading patent…
AssigneeAbbott Laboratories
InventorsClark A. Briggs, Murali Gopalakrishnan, David G. Mc Kenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
Estimating the term…
A variant human α7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human α7 nAChR. Nucleic acid molecules encoding the variant human α7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.
A polynucleotide encoding a variant of a wild-type human α7 subunit, wherein the polynucleotide encodes a polypeptide having an amino acid substitution at position valine-274 of the wild-type human α7 subunit polypeptide, and degenerate variants thereof.
An isolated and purified variant human α7 subunit, wherein the variant human α7 subunit comprises an amino acid substitution at position valine-274 of the wild-type human α7 polypeptide.
A method for identifying compounds that modulate nicotinic acetylcholine receptor (nAChR) activity, comprising:
A method for identifying a cytoprotective compound, comprising:
A compound useful for treating conditions associated with neurodegenerative processes, enzymatic function, affective disorders or immuno function, comprising a composition that regulates the function of the α7 variant.
A method of treating an individual having a condition associated with neurodegenerative processes, enzymatic function, affective disorders or immunofunction, comprising administering to said individual an effective amount of a compound that regulates the function of the α7 variant, in a pharmaceutically acceptable excipient.
A method of treating an individual having a condition associated with neurodegenerative processes, enzymatic function, affective disorders or immunofunction, comprising administering to said individual an effective amount of a compound that controls the gene expression of the α7 variant, in a pharmaceutically acceptable excipient.
A method of detecting target polynucleotides of human variant α7 subunit in a test sample, comprising:
A method for detecting cDNA of human variant α7 subunit mRNA in a test sample, comprising:
A purified polynucleotide or fragment thereof derived from human variant α7 subunit capable of selectively hybridizing to the nucleic acid of human variant α7 subunit, wherein said polynucleotide is SEQUENCE ID NO:
A polypeptide encoded by human variant α7 subunit polynucleotide wherein said polypeptide is SEQUENCE ID NO:
A monoclonal antibody which specifically binds to human variant α7 subunit having amino acid sequence SEQUENCE ID NO:
A method for detecting human variant α7 subunit in a test sample, comprising:
Dependencies are inferred from the claim text.